Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
EHA 2016
Innovative Therapies in CLL: Saturday, June 11
EHA 2016
,
EHA 2016 – Leukemia
,
EHA
Conference Correspondent
Acalabrutinib, a second-generation BTK inhibitor, in previously untreated CLL
Acalabrutinib, an irreversible selective BTK inhibitor, has demonstrated clinical efficacy in relapsed chronic lymphocytic leukemia (CLL). Preliminary data from an ongoing phase 1/2 study of acalabrutinib in 72 patients with previously untreated CLL show clinical activity at both dose schedules (100 mg twice daily, 200 mg once daily) that were tested. All patients experienced rapid reduction in lymphadenopathy. Treatment-related lymphocytosis occurred in 53% and resolved in 97% of these patients. The overall response rate was 96%, with median time to response of 2 months. Neither CLL progression nor Richter’s transformation has occurred to date. A phase 3 trial comparing acalabrutinib with ibrutinib in relapsed CLL is underway.
Ibrutinib plus bendamustine and rituximab in previously treated CLL/SLL: 2-year follow-up including MRD from the HELIOS study
Two-year data are now available from the international, double-blind, placebo-controlled, phase 3 study (HELIOS) comparing ibrutinib + bendamustine and rituximab (I+BR) and placebo + BR (BR) in patients with previously treated CLL/small lymphocytic lymphoma (SLL). At the first analysis (median follow-up, 17 months), progression-free survival (PFS) was significantly improved for I+BR versus BR. After 25.4 months, I+BR continues to show improvement in PFS (median not reached vs 14.2 months [BR]). Median overall survival is not yet reached in either arm. Rates of minimal residual disease (MRD)-negative response in the intent-to-treat population are 18% (I+BR) and 5% (BR). No new or unexpected safety signals are reported in this update.
Preliminary safety data from the phase 3b GREEN study of obinutuzumab (OBIN) alone or combined with chemotherapy for previously-untreated or relapsed CLL
GREEN is an ongoing phase 3b, open-label trial of OBIN alone or with chemotherapy in patients with previously untreated or relapsed/refractory CLL. The primary outcome is safety. In the study, patients receive OBIN alone or with chemotherapy at investigators’ discretion. Chemotherapy options include fludarabine plus cyclophosphamide (FC) for fit patients, chlorambucil (clb) for unfit patients, and bendamustine (B). Median observation time is 12.7 months to date. Findings are summarized below, and fit the known safety profile of OBIN.
Related Articles
Educating Caregivers and Looking at Patients’ Quality of Life
By
Nikhil Munshi
EHA
,
EHA 2016
Videos
Read Article
Finding Cost-Effective Ways to Good Outcomes
By
Nikhil Munshi
EHA
,
EHA 2016
Videos
Read Article
5-Azacitidine plus Checkpoint Inhibitor May Enhance Outcomes in Patients with De Novo and Relapsed AML
EHA 2016 – Leukemia
,
EHA
Conference Correspondent
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Addressing Cancer Health Disparities: The No One Left Alone Initiative
Rohan Nathwani
,
Arva Patel
,
Warner Kornberg
,
Asutosh Gor, MD
,
Sashi Naidu, MD
,
Viral Rabara, MD
,
Niyati Nathwani, MD
,
Kashyap Patel, MD
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma